SARM Antibody
- 产品详情
- 实验流程
- 背景知识
Application ![]()
| WB, IF, E |
---|---|
Primary Accession | Q6SZW1 |
Other Accession | NP_055892, 154090976 |
Reactivity | Human, Mouse, Rat |
Host | Rabbit |
Clonality | Polyclonal |
Isotype | IgG |
Calculated MW | 79388 Da |
Concentration (mg/ml) | 1 mg/mL |
Conjugate | Unconjugated |
Application Notes | SARM antibody can be used for detection of SARM by Western blot at 1 - 2 µg/mL. For immunofluorescence start at 20 µg/mL. |
Gene ID | 23098 |
---|---|
Other Names | Sterile alpha and TIR motif-containing protein 1, Sterile alpha and Armadillo repeat protein, Sterile alpha motif domain-containing protein 2, MyD88-5, SAM domain-containing protein 2, Tir-1 homolog, SARM1, KIAA0524, SAMD2, SARM |
Target/Specificity | SARM1; At least three alternatively spliced transcript variants encoding distinct isoforms have been observed. SARM antibody recognize the longest isoform. |
Reconstitution & Storage | SARM antibody can be stored at 4℃ for three months and -20℃, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures. |
Precautions | SARM Antibody is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | SARM1 |
---|---|
Function | NAD(+) hydrolase, which plays a key role in axonal degeneration following injury by regulating NAD(+) metabolism (PubMed:25908823, PubMed:27671644, PubMed:28334607). Acts as a negative regulator of MYD88- and TRIF-dependent toll-like receptor signaling pathway by promoting Wallerian degeneration, an injury-induced form of programmed subcellular death which involves degeneration of an axon distal to the injury site (PubMed:15123841, PubMed:16964262, PubMed:20306472, PubMed:25908823). Wallerian degeneration is triggered by NAD(+) depletion: in response to injury, SARM1 is activated and catalyzes cleavage of NAD(+) into ADP-D-ribose (ADPR), cyclic ADPR (cADPR) and nicotinamide; NAD(+) cleavage promoting cytoskeletal degradation and axon destruction (PubMed:25908823, PubMed:28334607, PubMed:30333228, PubMed:31128467, PubMed:31439792, PubMed:31439793, PubMed:32049506, PubMed:32828421, PubMed:33053563). Also able to hydrolyze NADP(+), but not other NAD(+)-related molecules (PubMed:29395922). Can activate neuronal cell death in response to stress (PubMed:20306472). Regulates dendritic arborization through the MAPK4-JNK pathway (By similarity). Involved in innate immune response: inhibits both TICAM1/TRIF- and MYD88-dependent activation of JUN/AP-1, TRIF-dependent activation of NF-kappa-B and IRF3, and the phosphorylation of MAPK14/p38 (PubMed:16964262). |
Cellular Location | Cytoplasm. Cell projection, axon {ECO:0000250|UniProtKB:Q6PDS3}. Cell projection, dendrite {ECO:0000250|UniProtKB:Q6PDS3}. Synapse {ECO:0000250|UniProtKB:Q6PDS3}. Mitochondrion Note=Associated with microtubules. {ECO:0000250|UniProtKB:Q6PDS3} |
Tissue Location | Predominantly expressed in brain, kidney and liver. Expressed at lower level in placenta. |
For Research Use Only. Not For Use In Diagnostic Procedures.
Provided below are standard protocols that you may find useful for product applications.
BACKGROUND
SARM Antibody: Toll-like receptors (TLRs) are signaling molecules that recognize different microbial products during infection and serve as an important link between the innate and adaptive immune responses. SARM (SAM and ARM-containing protein), along with other molecules such as TIRP, TRIF, TIRAP, and MyD88, is thought to serve as an adaptor protein for the TLRs that allows for the activation of downstream kinases and NF-κB, and ultimately the expression of proteins involved in host defense. While SARM has not been conclusively shown to associate directly with TLRs, the presence of a Toll-interleukin-1 (TIR) domain in SARM is consistent with a role as a signaling molecule.
REFERENCES
Vogel SN, Fitzgerald KA, and Fenton MJ. TLRs: differential adapter utilization by toll-like receptors mediates TLR-specific patterns of gene expression. Mol. Interv. 2003; 3:466-77.
Takeda K, Kaisho T, and Akira S. Toll-like receptors. Annu. Rev. Immunol. 2003; 21:335-76.
Janeway CA Jr and Medzhitov R. Innate immune recognition. Annu. Rev. Immunol. 2002; 20:197-216.
O’Neill LAJ, Fitzgerald FA, and Bowie AG. The Toll-IL-1 receptor adaptor family grows to five members. Trends in Imm. 2003; 24:286-9.

终于等到您。ABCEPTA(百远生物)抗体产品。
点击下方“我要评价 ”按钮提交您的反馈信息,您的反馈和评价是我们最宝贵的财富之一,
我们将在1-3个工作日内处理您的反馈信息。
如有疑问,联系:0512-88856768 tech-china@abcepta.com.